TCERG1L
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| transcription elongation regulator 1 like | Ensembl:ENSG00000176769 | HGNC:HGNC:23533 | PA134864258 | 10q26.3 |
GO terms in TCERG1L
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0070063 | RNA polymerase binding |
| CC | IBA | GO:0005634 | nucleus |
Gene expression in normal tissue: TCERG1L
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in TCERG1L
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD670 | ML 210 | 4 |
| iGMDRD546 | BMS-754807 | 4 |
| iGMDRD79 | Gemcitabine | 1 |
| iGMDRD781 | Sirolimus | 1 |
| iGMDRD405 | PIK-75 | 3 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD126 | Tipifarnib | 2 |
| iGMDRD248 | BRD4354 | 1 |
| iGMDRD177 | Teniposide | 4 |
| iGMDRD211 | (1S,3R)-RSL3 | 3 |
| iGMDRD154 | NSC23766 | 4 |
| iGMDRD634 | SCHEMBL2608041 | 3 |
| iGMDRD314 | Tanespimycin | 1 |
| iGMDRD434 | BMS-536924 | 3 |
| iGMDRD271 | Brefeldin A | 6 |
| iGMDRD474 | Avrainvillamide | 2 |
| iGMDRD138 | PX 12 | 2 |
| iGMDRD158 | NSC141540 | 4 |
| iGMDRD802 | 4-methylfasudil | 4 |
| iGMDRD505 | Pevonedistat | 1 |
| iGMDRD300 | Tozasertib | 2 |
| iGMDRD451 | Serdemetan | 2 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD367 | Ro 28-1675 | 2 |
| iGMDRD398 | Sepantronium | 3 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD506 | Fedratinib | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in TCERG1L
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.